Selective serotonin reuptake inhibitor or serotonin‐norepinephrine reuptake inhibitors and epidemiological characteristics associated with prenatal diagnosis of congenital heart disease
| Autor: | Thushari I. Alahakoon, Gary F. Sholler, Adrienne Kirby, Sarah J. Melov, Prayatna Singh Shetty, David S. Winlaw, Dharmintra Pasupathy |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Heart Defects Congenital 0301 basic medicine Postpartum depression medicine.medical_specialty Serotonin reuptake inhibitor Population 030105 genetics & heredity Tertiary Care Centers Young Adult 03 medical and health sciences 0302 clinical medicine Pregnancy Prenatal Diagnosis medicine Humans Bipolar disorder Serotonin and Noradrenaline Reuptake Inhibitors education Genetics (clinical) Retrospective Studies education.field_of_study 030219 obstetrics & reproductive medicine business.industry Obstetrics Obstetrics and Gynecology medicine.disease Mood Prenatal Exposure Delayed Effects Anxiety Female New South Wales medicine.symptom business Selective Serotonin Reuptake Inhibitors Cohort study |
| Zdroj: | Prenatal Diagnosis. 41:35-42 |
| ISSN: | 1097-0223 0197-3851 |
| Popis: | Objective Identify early pregnancy associations of congenital heart disease (CHD) in a multiethnic cohort. Methods This retrospective observational cohort study compared the general obstetric population to women who gave birth at a referral centre in Australia between 2012 and 2017, after 20 weeks' of gestation, with a pregnancy affected by CHD. We defined mood disorder and anxiety as a history of self-reported or medically diagnosed anxiety, depression, postpartum depression or bipolar disorder. Results We compared epidemiological factors between 30 842 general obstetric patients and 470 obstetric patients with a fetus affected by CHD. Multivariate analysis showed independent associations between CHD and use of selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) in the first trimester (relative risk [RR] 4.14, 95% CI 2.58-6.65), history of anxiety or mood disorder with no SSRI/SNRI first trimester (RR 2.26, 95% CI 1.82-2.82), folate and/or pregnancy multivitamin use in the first trimester (RR 0.68, 95% CI 0.54-0.86) and increased risk with maternal age >40 years (RR 2.30, 95% CI 1.57-3.38). Conclusions Our data show maternal mood disorders with and without SSRI or SNRI use, maternal age >40 years and lack of multivitamin/folate use to be independently associated with CHD in pregnancy. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text